↓ Skip to main content

Dove Medical Press

Article Metrics

Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients

Overview of attention for article published in Therapeutics and Clinical Risk Management, May 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (60th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
3 tweeters
googleplus
1 Google+ user

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
14 Mendeley
Title
Functional and histological improvement after everolimus rescue of chronic allograft dysfunction in renal transplant recipients
Published in
Therapeutics and Clinical Risk Management, May 2015
DOI 10.2147/tcrm.s84030
Pubmed ID
Authors

Kai Ming Chow, Cheuk Chun Szeto, Fernand Mac-Maune Lai, Cathy Choi-Wan Luk, Bonnie Ching-Ha Kwan, Chi Bon Leung, Philip Kam-Tao Li

Abstract

We tested the strategy of mTOR inhibitors with calcineurin inhibitor minimization in renal transplant recipients with known chronic allograft dysfunction. In this open-label, single-arm study, renal transplant patients were recruited after biopsy-confirmed chronic allograft dysfunction in the absence of acute rejection episode within 2 months, with proteinuria <0.8 g/day, and serum creatinine <220 μmol/L or estimated glomerular filtration rate >40 mL/min/1.73 m(2). They were converted to everolimus (aiming for trough everolimus level 3-8 ng/mL) with cyclosporine minimization, to assess the effect on renal function, rate of glomerular filtration rate decline, and longitudinal transplant biopsy at 12 months. Seventeen Chinese patients (median transplant duration, 4.2 years) were recruited; no patients discontinued study medication. The mean slope of the glomerular filtration rate over time was -4.31±6.65 mL/min/1.73 m(2) per year in the year before everolimus, as compared with 1.29±5.84 mL/min/1.73 m(2) per year in the 12 months of everolimus therapy, a difference of 5.61 mL/min/1.73 m(2) per year (95% confidence interval [CI], 0.40-10.8) favoring everolimus therapy (P=0.036). Serial renal biopsy histology showed significant decrease of tubular atrophy (15.7%±11.3% versus 7.1%±7.3%, P=0.005) and interstitial fibrosis (14.8%±11.5% versus 7.2%±8.2%, P=0.013). Intrarenal expression of TGF-β1 mRNA showed a nonsignificant decrease after everolimus treatment. In renal transplant recipients with biopsy-confirmed chronic allograft dysfunction, we found a significant beneficial effect of everolimus rescue therapy and calcineurin inhibitor minimization strategy on the improvement of glomerular filtration rate decline rate. In secondary analysis, everolimus was shown to slow down the disease progression by reducing the tubular atrophy and interstitial fibrosis scoring.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Russia 1 7%
Unknown 13 93%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 21%
Researcher 2 14%
Other 2 14%
Student > Bachelor 2 14%
Student > Ph. D. Student 1 7%
Other 3 21%
Unknown 1 7%
Readers by discipline Count As %
Medicine and Dentistry 6 43%
Mathematics 1 7%
Biochemistry, Genetics and Molecular Biology 1 7%
Agricultural and Biological Sciences 1 7%
Computer Science 1 7%
Other 1 7%
Unknown 3 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 May 2015.
All research outputs
#6,635,036
of 12,485,238 outputs
Outputs from Therapeutics and Clinical Risk Management
#373
of 922 outputs
Outputs of similar age
#88,664
of 232,685 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#10
of 28 outputs
Altmetric has tracked 12,485,238 research outputs across all sources so far. This one is in the 46th percentile – i.e., 46% of other outputs scored the same or lower than it.
So far Altmetric has tracked 922 research outputs from this source. They receive a mean Attention Score of 4.1. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 232,685 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.